LuciBriga 90 — Brigatinib 90 mg, 30 pcs, Lucius

LuciBriga 90 — Brigatinib Tablets 90 mg, 30 Tablets

Product code: 504

16986₴ 18506₴ -8% On order · from 10 days

Dosage

90 mg 180 mg
1
Active ingredient
Dosage form Tablets
Tablets per pack 30

LuciBriga 90 is an advanced targeted antineoplastic agent belonging to the tyrosine kinase inhibitor (TKI) class, indicated for the treatment of non-small cell lung cancer. The active pharmaceutical ingredient is brigatinib at a strength of 90 mg supplied as film-coated oral tablets (Brigatinib Tablets 90 mg). The product is developed and manufactured by Lucius Pharmaceuticals.

Brigatinib is a potent, selective oral inhibitor of anaplastic lymphoma kinase (ALK) and ROS1 receptor tyrosine kinase. It effectively suppresses ALK kinase activity (including resistance mutations responsible for resistance to first-generation ALK inhibitors) and exhibits superior blood-brain barrier penetration, ensuring excellent control of brain metastases.

Supplied in a package containing 30 tablets of 90 mg. Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of LuciBriga 90 mg:

  • ✅ Potent ALK & ROS1 Inhibitor: Highly effective suppression of mutant kinases driving tumor growth.
  • ✅ Overcoming Resistance: Active in tumors resistant to prior therapy with other ALK inhibitors.
  • ✅ High CNS Efficacy: Excellent blood-brain barrier penetration for intracranial lesion control.
  • ✅ Convenient Oral Dosing: Taken orally once daily regardless of food intake.
  • ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Alunbrig).

LuciBriga 90 is supplied as film-coated tablets for oral administration.

Qualitative and Quantitative Composition per Tablet:

  • Active Ingredient: Brigatinib — 90 mg.
  • Excipients: Lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, colloidal anhydrous silica. Coating: hypromellose, titanium dioxide, macrogol, colorants.

Packaging and Presentation: Film-coated tablets, 90 mg strength. Each package contains 30 tablets along with prescribing information. Labeled with LuciBriga 90 (Brigatinib Tablets 90 mg) and Lucius Pharmaceuticals corporate graphics.

Pharmacodynamics:
Brigatinib is a tyrosine kinase inhibitor targeting ALK, ROS1, and insulin-like growth factor 1 receptor (IGF-1R). Brigatinib has demonstrated the ability to inhibit ALK autophosphorylation and ALK-mediated phosphorylation of downstream signaling proteins, inducing tumor cell apoptosis. The drug is active against multiple crizotinib-resistant mutations.

Pharmacokinetics:

  • Absorption: Following oral administration, brigatinib is well absorbed; peak plasma concentration (Tmax) is achieved within approximately 1 to 4 hours. Food intake has no clinically significant effect on bioavailability.
  • Distribution: Human plasma protein binding is moderate (approx. 91%). Penetrates the central nervous system.
  • Metabolism: Extensively metabolized in the liver, primarily via CYP2C8 and CYP3A4 enzymes.
  • Elimination: Excreted predominantly via feces (approx. 65% as metabolites and unchanged drug) and renally (approx. 25%). Terminal elimination half-life (T1/2) averages approximately 24 hours.

LuciBriga 90 is indicated in adult patients for:

  • Non-Small Cell Lung Cancer (NSCLC): Treatment of adult patients with ALK-positive metastatic non-small cell lung cancer who have progressed on crizotinib or other ALK inhibitors, as well as for first-line therapy.

LuciBriga 90 is administered orally once daily every day at approximately the same time.

Dosing Regimen:
The recommended starting dose is 90 mg (one 90 mg tablet) once daily for the first 7 days. If tolerated during the initial week, the dose should be increased to the recommended standard maintenance dose of 180 mg once daily (two 90 mg tablets or one 180 mg tablet).

Administration Guidelines:
Tablets can be taken regardless of food intake with water. Tablets must be swallowed whole; do not break, crush, or chew. If a dose is missed or vomiting occurs after ingestion, take the next dose at the scheduled time (do not double doses).

Administration of LuciBriga 90 is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to brigatinib or any excipient (including lactose intolerance).
  • Pregnancy and Lactation: Strictly contraindicated in pregnant or breastfeeding women.
  • Pediatric Population: Safety and efficacy in patients under 18 years have not been established.
  • Severe Hepatic or Renal Impairment: Pronounced liver or kidney dysfunction (requiring dosage adjustment).

Brigatinib is metabolized by CYP2C8 and CYP3A4 enzymes:

  • Strong CYP3A4 Inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir): May significantly elevate brigatinib plasma concentrations (avoid concurrent use).
  • Strong CYP3A4 Inducers (rifampicin, carbamazepine, phenytoin, St. John's Wort): Significantly decrease brigatinib blood concentrations and reduce efficacy (avoid concurrent use).
  • Transporter Substrates: Brigatinib may affect certain transport systems (P-gp, BCRP).

Pregnancy:
LuciBriga 90 is contraindicated during pregnancy. Based on its mechanism of action, brigatinib may cause fetal harm and embryotoxicity. Females of reproductive potential and male partners must utilize effective reliable contraception during treatment and for at least 4 months (for females) and 3 months (for males) following the final dose.

Lactation:
Excretion of brigatinib into human breast milk is unstudied. Breastfeeding must be discontinued during treatment.

The most frequent and clinically significant adverse reactions include:

  • Gastrointestinal Tract: Diarrhea, nausea, vomiting, constipation, abdominal pain.
  • Laboratory Abnormalities: Elevated blood creatine phosphokinase (CPK), increased amylase and lipase, hyperglycemia, anemia, lymphopenia.
  • General Disorders: Fatigue, myalgia, arthralgia, arterial hypertension, cough.
  • Serious Effects: Pulmonary adverse reactions (pneumonitis/interstitial lung disease, particularly during the first days of treatment), bradycardia, visual disturbances.

Symptoms:
Specific acute overdose symptoms of brigatinib are unestablished. Anticipated manifestations include exacerbated adverse reactions (gastrointestinal, elevated CPK, bradycardia).

Treatment:
No specific antidote exists. In case of overdose, discontinue treatment and initiate supportive and symptomatic care under continuous vital function monitoring.

Storage Requirements for LuciBriga 90 mg:

  • 🌡️ Temperature Range: Store in original packaging in a dry place protected from light at temperatures below 30 °C.
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic antineoplastic agent).
  • ⏳ Shelf Life: Stated on carton and blister pack. Don't use past expiration date. Prescription-only oncology medicine.

To verify authenticity of genuine LuciBriga 90 mg manufactured by Lucius Pharmaceuticals, inspect the following security and visual features:

  • ✅ Security Hologram & Scratch Code: Outer carton features an official Lucius Pharmaceuticals anti-counterfeit holographic seal with a scratch-off verification code for online validation via the manufacturer's official portal.
  • ✅ Corporate Branding: High-resolution printing displaying Lucius Pharmaceuticals graphics, Brigatinib Tablets 90 mg, and 30 Tablets count.
  • ✅ Factory Markings: Clearly printed Batch No., Mfg. Date, and Exp. Date matching across outer packaging and internal blister packs.
  • ✅ Prescribing Information: Includes an official product leaflet inside the outer carton.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 15.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00